Zobrazeno 1 - 7
of 7
pro vyhledávání: '"B L, Pilmer"'
Autor:
Maria Claudia Perez, B. L. Pilmer, Stuart Atkinson, M. Lee, Prateek Sharma, Nicholas J. Shaheen, David A. Peura
Publikováno v:
Alimentary Pharmacology & Therapeutics. 29:731-741
Summary Background Dexlansoprazole MR employs a dual delayed-release delivery system that extends drug exposure and prolongs pH control compared with lansoprazole. Aim To assess the efficacy and safety of dexlansoprazole MR in healing erosive oesopha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18170c4ca651a0283f559e948fdb2959
https://doi.org/10.1111/j.1365-2036.2009.03933.x
https://doi.org/10.1111/j.1365-2036.2009.03933.x
Autor:
Y. L. n Chiu, J.-Q. Huang, Cindy James, B. L. Pilmer, Abr Thomson, S. A. Appelman, Subbaramiah Sridhar, R. G. Keith, D. R. Goldwater, Richard H. Hunt
Publikováno v:
Alimentary Pharmacology & Therapeutics. 16:425-433
Aim: To compare the effect of lansoprazole, 30 mg once daily, with that of pantoprazole, 40 mg once daily, for the inhibition of gastric acid secretion. Methods: Two randomized, single-blind, two-way, crossover studies were conducted in 74 healthy ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99a3e5a4a0fbe921caf874dd9d746ab1
https://doi.org/10.1046/j.1365-2036.2002.01168.x
https://doi.org/10.1046/j.1365-2036.2002.01168.x
Publikováno v:
Alimentary Pharmacology & Therapeutics. 14:345-352
Aim: To study the potential pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline at steady state. Methods: Theophylline 200 mg extended-release formulation was administered twice daily on days 1–11 to 30 healthy, non-sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa2538080de9ee5b6c632152a6de57dd
https://doi.org/10.1046/j.1365-2036.2000.00703.x
https://doi.org/10.1046/j.1365-2036.2000.00703.x
Publikováno v:
Alimentary pharmacologytherapeutics. 20(8)
Some patients requiring acid suppression may be unable to take oral medications.To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients.The study included 87 Heli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::066b3881168557ccaac0363c9556ef78
https://pubmed.ncbi.nlm.nih.gov/15479360
https://pubmed.ncbi.nlm.nih.gov/15479360
Publikováno v:
Alimentary pharmacologytherapeutics. 19(10)
To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.Twenty-nine subjects received lansoprazole orally on days 1-7 and intravenous lansoprazole in NaCl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f59a7d207adad7ecfde0db79cdb8affb
https://pubmed.ncbi.nlm.nih.gov/15142201
https://pubmed.ncbi.nlm.nih.gov/15142201
Publikováno v:
Alimentary pharmacologytherapeutics. 15(11)
To compare the 24-h intragastric pH effects of simplified lansoprazole suspension, 30 mg, administered nasogastrically, with pantoprazole, 40 mg, administered intravenously.Thirty-six healthy adults were enrolled and given simplified lansoprazole sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed6deab90d79286f366120d213b102b7
https://pubmed.ncbi.nlm.nih.gov/11683695
https://pubmed.ncbi.nlm.nih.gov/11683695
Publikováno v:
Alimentary pharmacologytherapeutics. 14(3)
To study the potential pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline at steady state.Theophylline 200 mg extended-release formulation was administered twice daily on days 1-11 to 30 healthy, non-smoking males. On d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3f20c53f872f5112f70f1d3b3eca2fb
https://pubmed.ncbi.nlm.nih.gov/10735929
https://pubmed.ncbi.nlm.nih.gov/10735929